<DOC>
	<DOCNO>NCT02946684</DOCNO>
	<brief_summary>This project seek determine whether estradiol suppression achieve adjuvant treatment aromatase inhibitor improve end-follicular luteal phase parameter IVF . 128 patient randomize either placebo active treatment .</brief_summary>
	<brief_title>Effect Addition Aromatase Inhibitor Ovarian Stimulation Therapy IVF Treatment</brief_title>
	<detailed_description>The aim study investigate whether detrimental effect ovarian stimulation outcome fresh embryo transfer cycle ameliorate co-treatment aromatase inhibitor ? The research question : 1 . Can impact ovarian stimulation late follicular phase sex steroid level ( hence endometrial receptivity ) mitigate co-treatment aromatase inhibitor ovarian stimulation ? 2 . Does co-treatment aromatase inhibitor 'normalize ' endocrinology luteal phase</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Indication IVF treatment : tubal , male , medical Antral follicle count ( AFC ) 10 25 included Age &lt; 40 Previous anticipate poor response ovarian stimulation IVF &lt; 4 oocyte obtain ≥ 3 previous IVF cycle result pregnancy ( negative shCG ) Anti Müllerian Hormone ( AMH ) &lt; 4 pmol ( ) Cycle day ( CD ) 23 Follicle Stimulating Hormone &gt; 12 Polycystic Ovarian Syndrome Smoking BMI ≥ 31 Risk developping Ovarian Hyperstimulation Syndrome Allergy towards drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>